These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 16421494)

  • 1. Primary cytomegalovirus disease after five years of antiviral prophylaxis.
    Kijpittayarit S; Deziel P; Eid AJ; Razonable RR
    Transplantation; 2006 Jan; 81(1):137-8. PubMed ID: 16421494
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytomegalovirus prophylaxis with IV ganciclovir in lung transplant recipients: the long and the short of it!
    Orens JB
    Chest; 1999 Nov; 116(5):1152-3. PubMed ID: 10559066
    [No Abstract]   [Full Text] [Related]  

  • 3. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
    J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preemptive therapy for cytomegalovirus infections and the development of resistance to ganciclovir.
    Kroes AC; Kalpoe JS
    J Infect Dis; 2002 Sep; 186(5):724-5; author reply 725-6. PubMed ID: 12195366
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk factors, survival, and impact of prophylaxis length in cytomegalovirus-seropositive lung transplant recipients: A prospective, observational, multicenter study.
    Monforte V; Sintes H; López-Gallo C; Delgado M; Santos F; Zurbano F; Solé A; Gavaldá J; Borro JM; Redel-Montero J; Cifrian JM; Pastor A; Román A; Ussetti P
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28294487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation.
    Speich R; Thurnheer R; Gaspert A; Weder W; Boehler A
    Transplantation; 1999 Jan; 67(2):315-20. PubMed ID: 10075601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended ganciclovir prophylaxis in lung transplantation.
    Perreas KG; McNeil K; Charman S; Sharples LD; Wreghitt T; Wallwork J
    J Heart Lung Transplant; 2005 May; 24(5):583-7. PubMed ID: 15896756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylaxis of cytomegalovirus disease with intravenous ganciclovir in renal transplantation.
    Sancho A; Górriz JL; Crespo JF; Avila A; Alcaraz MJ; García Ramos JL; Pallardó LM
    Transplant Proc; 1999 Sep; 31(6):2337-8. PubMed ID: 10500606
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients.
    Boivin G; Goyette N; Gilbert C; Humar A; Covington E
    Transpl Infect Dis; 2005; 7(3-4):166-70. PubMed ID: 16390409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
    Singh N
    Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.
    Limaye AP; Raghu G; Koelle DM; Ferrenberg J; Huang ML; Boeckh M
    J Infect Dis; 2002 Jan; 185(1):20-7. PubMed ID: 11756977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation.
    Chmiel C; Speich R; Hofer M; Michel D; Mertens T; Weder W; Boehler A
    Clin Infect Dis; 2008 Mar; 46(6):831-9. PubMed ID: 18269330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial cytomegalovirus prophylaxis with ganciclovir: no guarantee for prevention of late serious manifestations of CMV after solid organ transplantation.
    Zandberg M; de Maar EF; Hofker HS; Homan van der Heide JJ; Rosati S; van Son WJ
    Neth J Med; 2005 Nov; 63(10):408-12. PubMed ID: 16301763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis.
    Wiita AP; Roubinian N; Khan Y; Chin-Hong PV; Singer JP; Golden JA; Miller S
    Transpl Infect Dis; 2012 Jun; 14(3):248-58. PubMed ID: 22385394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prophylaxis of cytomegalovirus primary infection with short-term ganciclovir therapy.
    Lauzurica R; Bayés B; Frías C; Hernández A; Jimenez A; Fontseré N; Romero R
    Transplant Proc; 2003 Aug; 35(5):1751-2. PubMed ID: 12962781
    [No Abstract]   [Full Text] [Related]  

  • 17. Ganciclovir susceptibilities and analysis of UL97 region in cytomegalovirus (CMV) isolates from bone marrow recipients with CMV disease after antiviral prophylaxis.
    Erice A; Borrell N; Li W; Miller WJ; Balfour HH
    J Infect Dis; 1998 Aug; 178(2):531-4. PubMed ID: 9697737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients.
    Boivin G; Goyette N; Gilbert C; Roberts N; Macey K; Paya C; Pescovitz MD; Humar A; Dominguez E; Washburn K; Blumberg E; Alexander B; Freeman R; Heaton N; Covington E
    J Infect Dis; 2004 May; 189(9):1615-8. PubMed ID: 15116297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
    Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
    J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral dosing and efficacy for prophylaxis of cytomegalovirus disease in solid organ transplant recipients.
    Cochrane AB
    Am J Health Syst Pharm; 2006 Oct; 63(19 Suppl 5):S17-21. PubMed ID: 16990640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.